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Introduction: The seventh edition of the tumor, node, metastasis
classification for lung cancer has been published in 2009. The aim of
this study is to evaluate time trends of surgical outcomes and
clinicopathologic factors in patients with pathological stage I non-
small cell lung cancer according to the seventh edition of the tumor,
node, metastasis classification.
Methods: We retrospectively reviewed the clinicopathologic char-
acteristics of 1249 patients with pathological stage I non-small cell
lung cancer from Taipei Veterans General Hospital between January
1980 and December 2006, during the three periods of 1980–1990,
1991–2000, and 2001–2006. The overall survival, disease-specific
survival, and postrecurrence survival were analyzed.
Results: The 5-year overall survival rates during the three periods
improved significantly: 53.7, 59.9, and 69.3%, respectively (p 
0.001). The 2-year postrecurrence survival rates during the three
periods improved significantly: 10.6, 25.4, and 43.2%, respectively
(p  0.001). The percentage of female patients increased during
each period: 15.4, 24.9, and 32.0%, respectively (p  0.001). The
percentage of adenocarcinoma also increased during each period:
51.2, 62.2, and 74.9%, respectively (p  0.001). Tumor size during
each period was 3.2, 3.2, and 2.8 cm, tending to be smaller when
diagnosed in the last period (p  0.001). The overall survival in
patients with squamous cell carcinoma and those undergoing pneu-
monectomy or bilobectomy did not improve over time.
Conclusions: Stage migration, improved postrecurrence survival,
increased frequencies of female gender and adenocarcinoma, and
decreased tumor size lead to improved overall survival over the past
three decades.
Key Words: Non-small cell lung cancer, Time trend, Survival,
Recurrence, Histology.
(J Thorac Oncol. 2012;7: 397–405)
Since 1985, lung cancer has been the most common cancerdiagnosed each year worldwide.1 Survival for patients
with lung cancer has only modest improved over the last two
or three decades, with 5-year survival ranges between 6 and
18%.2–4 The main cause of poor survival is that a majority of
lung cancer patients were diagnosed at advanced stage.5
Surgical resection is the treatment of choice for early-stage
non-small cell lung cancer (NSCLC).6,7 Tumor recurrence is
the main cause of treatment failure after surgical resection.7,8
The seventh edition of the tumor, node, metastasis
(TNM) classification for lung cancer has been published in
2009,9,10 and the criteria of stage I NSCLC have been
changed. In the fifth edition of the TNM classification for
lung cancer published in 1997, stage I NSCLC was subdi-
vided into IA (T1N0M0, tumor size 3 cm) and IB
(T2N0M0, tumor size 3 cm).11 In addition to tumor size
greater than 3 cm, the T2 descriptor also includes tumors that
invade the visceral pleura regardless of size, tumors that
involve the main bronchus 2 cm distal to the carina, and
tumors that result in associated atelectasis and obstructive
pneumonitis that extends to the hilar region but does not
involve the entire lung radiographically.11 In the seventh
edition of the TNM classification for lung cancer, T1 descrip-
tor have be classified into T1a (2 cm) and T1b (2 to 3
cm), whereas size-based T2 descriptor has be classified into
T2a (3 to 5 cm), T2b (5 to 7 cm), and T3 (7 cm).12
Stage I NSCLC was subdivided into IA (T1aN0M0,
T1bN0M0) and IB (T2aN0M0).13 As compared with the sixth
edition of the TNM classification, stage IA was not changed,
while stage IB was restricted to T2aN0M0.
The changes of the new staging system have been
validated in the literature.14–17 However, trends in overall
survival, disease-specific survival, and postrecurrence sur-
vival in stage I NSCLC of new staging system have not been
well demonstrated. In our previous studies, we have illus-
trated the prognostic factors in resected stage I NSCLC with
a diameter of 3 cm or less18 and in stage IB NSCLC greater
than 3 cm19 according to the sixth edition of the TNM
classification. We have also demonstrated that postrecurrence
survival in resected stage I NSCLC after recurrence was
poor.20,21 In this study, we focused on time trends of overall
survival, disease-specific survival, and postrecurrence sur-
vival in patients with pathological stage I NSCLC according
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to the seventh edition of the TNM classification over the last
three decades. Time trends in distribution of clinicopatho-
logic factors were also investigated.
PATIENTS AND METHODS
From January 1980 to December 2006, a total of 1505
patients underwent surgical resection for pathological stage I
NSCLC according to the sixth edition of the TNM classifi-
cation for lung cancer at Taipei Veterans General Hospital.
Among them, 1275 (84.7%) patients were reclassified as
pathological stage I NSCLC according to the seventh edition
of the TNM classification for lung cancer and were included
in this retrospective study. Patients died within 30 days after
surgery (surgical mortality) were excluded from survival
analysis. This study has been approved by the Institutional
Review Board of Taipei Veterans General Hospital. The time
trends of surgical outcomes and clinicopathologic factors
were evaluated separately during the periods of 1980–1990,
1991–2000, and 2001–2006. The preoperative staging
workup was done as previous described.18,19 Mediastinos-
copy was not a routine preoperative staging procedure and
was performed only when enlarged mediastinal lymph nodes
(diameter 1.0 cm) were shown by computed tomographic
(CT) scan. 18F-fluorodeoxyglucose positron emission tomog-
raphy (PET) was available as a staging modality in our
institute since 2003 and was not routinely performed preop-
eratively within the study period. No other staging diagnostic
test had been used. There was no major revision of patient
operability criteria and tumor resectability criteria during the
study period. Complete resection of lung cancer with medi-
astinal lymph node dissection/sampling was performed in all
patients as previously described.18,19 No patient received
adjuvant chemotherapy after surgical resection.
We reviewed the hospital charts of all patients to collect
data of clinicopathologic characteristics and survival. The
number of mediastinal lymph nodes and number of medias-
tinal lymph node stations dissected/sampled, including N1
and N2 nodes, was recorded from pathologic reports. Histo-
logical typing was determined according to the World Health
Organization classification.22 Determination of disease stages
was based on the seventh edition of the TNM classification of
the American Joint Commission and the International Union
Against Cancer.9,10 All patients were followed up at our
outpatient department quarterly in the first 2 years after
resection and semiannually thereafter. The length of survival
was defined as the interval in months between the date of
surgical resection and the date of either death or the last
follow-up. The period of disease-specific survival was de-
fined as the interval in months between the date of surgical
resection and the date the first site of recurrence was found.
The length of postrecurrence survival was defined as the
interval in months from the date of initial recurrence identi-
fied to death or the date of the last follow-up.
The overall survival, disease-specific survival, and
postrecurrence survival were calculated by the Kaplan-Meier
method.23 To compare between groups with respect to cate-
gorical and continuous variables, the 2 test, the independent
sample t test, or the one-way analysis of variance test was
used as appropriate. The log-rank test was used to compare
between groups of different time periods. Univariate and
multivariate analyses were performed by means of the Cox
proportional hazards model using SPSS software (version
16.0; SPSS, Chicago, IL). Only variables with a p value0.1
after the univariate analysis were entered into the multivariate
analysis. Statistical analysis was considered to be significant
when p  0.05.
RESULTS
The median follow-up time for these 1275 patients with
surgically resected stage I NSCLC was 85.4 months (95%
confidence interval, 77.4–93.3 months). There were 26 pa-
tients died within 30 days after surgery and were excluded
from survival analysis. Surgical mortality rate during the
three periods (1980–1990, 1991–2000, and 2001–2006) was
2.6, 2.6, and 1.1%, respectively. The characteristics of these
1249 patients are listed in Table 1. The number of patients
during each period was 260 (20.8%), 526 (42.1%), and 463
(37.1%), respectively. At last follow-up, 309 (24.7%) patients
TABLE 1. Characteristics of 1249 Patients of Pathological
Stage I Non-small Cell Lung Cancer
Variables Patients
Age, yr (mean  SD) 66.0  10.0
Sex, n (%)
Male 930 (74.5)
Female 319 (25.5)
Time period, n (%)
1980–1990 260 (20.8)
1991–2000 526 (42.1)
2001–2006 463 (37.1)
Smoking exposure, pack-years
Never 389 (31.1)
1–20 169 (13.5)
20 499 (40.0)
Unknown 192 (15.4)
Tumor size, cm (mean  SD) 3.1  1.2
Histological type, n (%)
Squamous cell carcinoma 388 (31.1)
Adenocarcinoma 807 (64.5)
Large cell carcinoma 37 (3.0)
Adenosquamous carcinoma 12 (1.0)
Others 5 (0.4)
T descriptor, n (%)
T1a 255 (20.4)
T1b 299 (23.9)
T2a 695 (55.7)
Extent of pulmonary resection, n (%)
Sublobar resection 150 (12.0)
Lobectomy 945 (75.6)
Bilobectomy 82 (6.6)
Pneumonectomy 72 (5.8)
Number of LNs dissected/sampled (mean  SD) 16.1  10.7
Number of LN stations dissected/sampled (mean  SD) 4.1  1.9
LN, lymph node.
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developed tumor recurrence. The 5- and 10-year overall
survival rates were 61.8 and 38.9%, respectively (Figure 1A).
The 5-year overall survival rates in 1980–1990, 1991–2000,
and 2001–2006 were 53.7, 59.9, and 69.3%, respectively
(Figure 1B). The overall survival significantly improved over
the last three decades (p  0.001). The 3-year disease-
specific survival rates in 1980–1990, 1991–2000, and 2001–
2006 were 70.7, 72.8, and 78.0%, respectively (Figure 1C).
The disease-specific survival rates were not significantly
different in the three time periods (p  0.167). The 2-year
postrecurrence survival rates in 1980–1990, 1991–2000, and
2001–2006 were 10.6, 25.4, and 43.2%, respectively (Figure
1D). The postrecurrence survival rate improved significantly
over the last three decades (p  0.001).
The relationship between clinicopathologic character-
istics and time periods (1980–1990, 1991–2000, and 2001–
2006) is listed in Table 2. The age at operation was signifi-
cantly older in time periods of 1991–2000 and 2001–2006 as
compared with that in 1980–1990 (p  0.001). The percent-
age of female patients increased during each period: 15.4,
24.9, and 32.0%, respectively (p 0.001). Tumor size during
each period was 3.2, 3.2, and 2.8 cm, being significantly
smaller when diagnosed in the last period (p  0.001). The
percentage of adenocarcinoma increased during each period:
FIGURE 1. A, Cumulative probability of overall survival in patients with surgically resected stage I non-small cell lung cancer.
B, Overall survival in patients with resected stage I non-small cell lung cancer according to time periods 1980–1990, 1991–
2000, and 2001–2006. C, Disease-specific survival in patients with resected stage I non-small cell lung cancer according to
time periods 1980–1990, 1991–2000, and 2001–2006. D, Postrecurrence survival in patients with resected stage I non-small
cell lung cancer according to time periods 1980–1990, 1991–2000, and 2001–2006. The log-rank test was used to compare
between groups.
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51.2, 62.2, and 74.9%, respectively. The percentage of squa-
mous cell carcinoma decreased during each period: 45.4,
34.0, and 19.7%, respectively (p  0.001). The percentage of
adenocarcinoma with bronchioloalveolar carcinoma (BAC)
component increased during each period: 10.4, 21.9, and
27.0% (p  0.001). The percentage of T1b during each
period was 32.7, 23.9, and 19.0%, being significantly de-
creased in the last two periods (p 0.001). The percentage of
T2a during each period was 47.3, 56.3, and 59.6%, being
significantly increased in the last two periods (p  0.001).
The percentage of pneumonectomy or bilobectomy decreased
during each period: 27.7, 12.7, and 3.2%, respectively. The
percentage of lobectomy or sublobar resection increased
during each period: 72.3, 87.3, and 96.8%, respectively (p 
0.001). The number of mediastinal lymph nodes dissected
increased during each period: 11.4, 16.6, and 20.4, respec-
tively (p  0.001). The number of mediastinal lymph node
stations dissected also increased during each period: 3.0, 4.2,
and 5.2, respectively (p  0.001). During the last period, 38
(8.2%) patients had PET-CT scan before operation, and 18
(3.9%) patients were detected with lung cancer by chest CT
screening.
We further investigated the survival trends of various
clinicopathologic factors. For male patients, the overall sur-
vival rate in time period 2001–2006 was significantly better
than that in 1980–1990 (p  0.007) and tended to be
significantly better than that in 1991–2000 (p  0.077)
(Figure 2A). For female patients, the overall survival rate in
time period 2001–2006 was significantly better than those in
1980–1990 (p  0.006) and 1991–2000 (p  0.012) (Figure
2B). For patients with adenocarcinoma, the overall survival
rate in time period 2001–2006 was significantly better than
those in 1980–1990 (p  0.001) and 1991–2000 (p  0.003)
(Figure 3A). The overall survival rate in 1991–2000 was
significantly better than that in 1980–1990 (p  0.003).
However, there was no significant difference in overall sur-
TABLE 2. Relationship Between Time Periods and Clinicopathologic Variables in Patients of Pathological Stage I Non-small
Cell Lung Cancer
Variables
Time Period
p1980–1990 (n  260) 1991–2000 (n  526) 2001–2006 (n  463)
Age, yr (mean  SD) 63.4  8.4 66.4  9.7 67.0  11.0 0.001
Sex, n (%)
Male 220 (84.6) 395 (75.1) 315 (68.0) 0.001
Female 40 (15.4) 131 (24.9) 148 (32.0)
Smoking exposure, pack-yearsa
Never 83 (33.1) 177 (36.0) 129 (41.0) 0.043
1–20 54 (21.5) 74 (15.1) 41 (13.0)
20 114 (45.4) 240 (48.9) 145 (46.0)
Tumor size, cm (mean  SD) 3.2  1.2 3.2  1.1 2.8  1.1 0.001
Histological type, n (%)
Squamous cell carcinoma 118 (45.4) 179 (34.0) 91 (19.7) 0.001
Adenocarcinoma with BAC component 27 (10.4) 115 (21.9) 125 (27.0)
Adenocarcinoma without BAC component 106 (40.8) 212 (40.3) 222 (47.9)
Others 9 (3.4) 20 (3.8) 25 (5.4)
T descriptor, n (%)
T1a 52 (20.0) 104 (19.8) 99 (21.4) 0.001
T1b 85 (32.7) 126 (23.9) 88 (19.0)
T2a 123 (47.3) 296 (56.3) 276 (59.6)
Extent of pulmonary resection, n (%)
Lobectomy or sublobar resection 188 (72.3) 459 (87.3) 448 (96.8) 0.001
Pneumonectomy or bilobectomy 72 (27.7) 67 (12.7) 15 (3.2)
PET-CT scan
Yes 38 (8.2) N/A
No 395 (85.3)
Unknown 30 (6.5)
Chest CT screening
Yes 18 (3.9) N/A
No 428 (92.4)
Unknown 17 (3.7)
Number of LNs dissected/sampled (mean  SD) 11.4  8.2 16.6  10.2 20.4  12.1 0.001
Number of LN stations dissected/sampled (mean  SD) 3.0  1.5 4.2  1.7 5.2  2.1 0.001
a Data are lacking in some patients.
BAC, bronchioloalveolar carcinoma; PET, positron emission tomography; CT, computed tomography; LN, lymph node.
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vival rates among the three time periods in patients with
squamous cell carcinoma (Figure 3B). Furthermore, no sig-
nificant difference in overall survival rates among the three
time periods was observed in both stage IA and stage IB
groups of patients with squamous cell carcinoma (data not
shown). To further examine the effect of histology on sur-
vival improvement over time, we conducted a Cox propor-
tional hazards model. For patients with adenocarcinoma, time
period was a significant prognostic factor for overall survival
in both univariate and multivariate analyses (Table 3). How-
ever, time period was not a significant prognostic factor for
patients with squamous cell carcinoma (Table 3). For patients
undergoing lobectomy or sublobar resection, the overall sur-
vival rate in time period 2001–2006 was significantly better
than those in 1980–1990 (p  0.001) and 1991–2000 (p 
0.006) (Figure 4A). Furthermore, the overall survival rate in
1991–2000 was significantly better than that in 1980–1990
(p  0.042). However, there was no significant difference in
overall survival rates among the three time periods in patients
undergoing pneumonectomy or bilobectomy (Figure 4B). The
frequency of tumor size greater than 3 cm was significantly
higher in patients undergoing pneumonectomy or bilobec-
tomy as compared with that in lobectomy or sublobar resec-
tion group (p  0.001). For patients undergoing pneumonec-
tomy or bilobectomy, there was no significant difference in
overall survival rates among the three time periods in both the
groups of stage IA and stage IB (data not shown).
DISCUSSION
This study investigated the time trends of survivals and
distribution of conventional clinicopathologic factors in pa-
tients with pathological stage I NSCLC. The overall survival
FIGURE 2. Overall survival in (A) male and (B) female pa-
tients, with resected stage I non-small cell lung cancer ac-
cording to time periods 1980–1990, 1991–2000, and 2001–
2006. The log-rank test was used to compare between
groups.
FIGURE 3. Overall survival in patients of resected stage I
non-small cell lung cancer with (A) adenocarcinoma and (B)
squamous cell carcinoma, according to time periods 1980–
1990, 1991–2000, and 2001–2006. The log-rank test was
used to compare between groups.
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and postrecurrence survival significantly improved over the
last three decades. The frequencies of female gender and
adenocarcinoma increased over the last three decades. Tumor
size at diagnosis significantly decreased in the most recent
period.
Although there was only modest improvement in sur-
vival for patients with lung cancer over the last two or three
decades,2–4 several reports published recently showed im-
proved survival over time.24–28 Kachroo et al.24 demonstrated
improved survival of patients with lung cancer from 1985 to
2004. Pitz et al.25 reported improved survival for patients
with NSCLC after 1997, especially for those undergoing
surgery. Survival rates in NSCLC patients undergoing sur-
gery are improving.26–28 Hanagiri et al.26 reported improved
surgical outcome in patients with NSCLC between 1979 and
2008. Koike et al.27 also reported improved surgical outcome,
with postoperative overall 5-year survival rates of 47.8% in
1989, 52.3% in 1994, and 62.0% in 1999. In this study, we
showed that overall survival in patients with pathological
stage I NSCLC significantly improved over the past three
decades.
Disease-specific survival rates in the three time periods
were not significantly different in our study. We observed
high discriminative difference between overall survival and
that lower in disease-specific survival. The age at operation
was significantly older in the last two periods. As patient age
TABLE 3. Univariate and Multivariate Analyses for Overall Survival in Patients with Pathological Stage I Adenocarcinoma and
Squamous Cell Carcinoma
Variables
Adenocarcinoma Squamous Cell Carcinoma
Univariate Analysis Multivariate Analysis Univariate Analysis Multivariate Analysis
HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p
Age 1.023 (1.012–1.034) 0.001 1.021 (1.007–1.035) 0.003 1.026 (1.009–1.043) 0.002 1.026 (1.008–1.045) 0.005
Gender
Female 1 1 1
Male 1.704 (1.335–2.169) 0.001 1.188 (0.882–1.603) 0.258 1.196 (0.710–2.016) 0.500
Time period
1980–1990 1 1 1
1991–2000 0.675 (0.522–0.873) 0.003 0.801 (0.592–1.083) 0.149 1.162 (0.874–1.547) 0.302
2001–2008 0.437 (0.322–0.593) 0.001 0.621 (0.408–0.945) 0.026 1.237 (0.850–1.800) 0.267
Smoking exposure 1.009 (1.005–1.013) 0.001 1.006 (1.002–1.011) 0.009 1.005 (1.001–1.009) 0.010 1.003 (0.999–1.008) 0.143
Tumor size
2 cm 1 1 1 1
2 to 3 cm 1.655 (1.225–2.236) 0.001 1.378 (0.987–1.925) 0.060 1.572 (1.092–2.262) 0.015 1.428 (0.962–2.122) 0.077
3 to 5 cm 2.230 (1.665–2.987) 0.001 1.807 (1.317–2.480) <0.001 1.266 (0.909–1.762) 0.163 1.205 (0.837–1.734) 0.315
Visceral pleural invasion
Absent 1 1
Present 1.021 (0.803–1.299) 0.865 0.983 (0.883–1.094) 0.753
Extent of pulmonary
resection
Lobectomy or sublobar
resection
1 1
Pneumonectomy or
bilobectomy
1.107 (0.785–1.561) 0.563 1.061 (0.797–1.414) 0.684
BAC component
No 1 1
Yes 0.589 (0.461–0.752) 0.001 0.705 (0.540–0.921) 0.010 N/A
PET-CT scan
No 1 1
Yes 1.452 (0.574–3.672) 0.430 0.896 (0.215–3.726) 0.880
Chest CT screening
No 1
Yes 0.047 (0.000–14.154) 0.293 N/Aa
Number of LNs dissected/
sampled
0.979 (0.967–0.990) 0.001 0.991 (0.974–1.008) 0.307 0.989 (0.976–1.002) 0.094 0.992 (0.974–1.010) 0.389
Number of LN stations
dissected/sampled
0.862 (0.810–0.918) 0.001 0.940 (0.854–1.035) 0.207 0.935 (0.872–1.002) 0.058 0.934 (0.844–1.035) 0.193
Bold indicates significance in multivariate analysis.
a There was no patient with squamous cell carcinoma detected by chest CT screening.
HR, hazard ratio; CI, confidence interval; BAC, bronchioloalveolar carcinoma; PET, positron emission tomography; CT, computed tomography; LN, lymph node.
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increases, the probability of comorbidity and subsequent
mortality due to other causes may also increase. We further
showed that postrecurrence survival significantly improved
over the last three decades. Time trends for postrecurrence
survival have not been well demonstrated in the literature.
Our previous studies have shown that treatment for recur-
rence and longer disease-free interval were prognostic factors
for better postrecurrence survival in patients with stage I
NSCLC.20,21 The percentage of no treatment for recurrence in
each period was 9.5, 11.2, and 5.0%, being significantly
decreased in the last period. The disease-free interval in each
period was 18.3, 15.7, and 21.3 months, being significantly
increased in the last period (p  0.012). The decrease of
patients receiving no treatment after recurrence and pro-
longed disease-free interval may be contributing factors for
improved postrecurrence survival. Furthermore, targeted
therapy emerged as a novel therapeutic strategy after 2001.
Seventeen (21.3%) of 80 patients with recurrence in the last
period have been treated with targeted therapy. As compared
with those without targeted therapy, the patients who have
received targeted therapy had significantly better postrecur-
rence survival (p  0.013). Targeted therapy may be another
contributing factor for improved postrecurrence survival. The
improvement in postrecurrence survival was a main reason
leading to improved overall survival in our study.
Another possible reason for the improvement of overall
survival is stage migration, including PET entering as a
preoperative staging modality recently, increased number of
mediastinal lymph nodes dissection, and widespread use of
high-resolution CT for screening of lung cancer. Morgensz-
tern et al.29 have reported significant stage migration in
patients with NSCLC after 2000. They suggested that the
most likely explanation for the shifting of patients with earlier
disease to advanced disease was the increased acceptance and
widespread use of PET scan for staging. We examined the
prognostic value of the use of PET-CT in patients with
adenocarcinoma and squamous cell carcinoma, and the use of
PET-CT scan was not a significant prognostic factor. PET-CT
scan was available for preoperative workup in our institute
since 2003 and was not routinely performed preoperatively
until 2008. Only 8.2% of patients had PET-CT scan in the last
period. The prognostic value of the use of PET-CT is not
conclusive in the current study.
Tumor size is a significant prognostic factor for stage I
NSCLC.7,8,12,17 With the widespread use of high-resolution
CT for screening of lung cancer, lung tumors with smaller
diameter, especially early-stage adenocarcinoma, were inci-
dentally detected more frequently. Several lung cancer
screening programs showed that the stage distribution shifted
to earlier stages and thus the curable possibility of lung
cancer increased.30,31 However, the risk of death from lung
cancer has not significantly reduced, and the existence of
lead-time bias was argued. A recent randomized trail reported
that screening with the use of low-dose CT may reduce
mortality from lung cancer.32 Hanagiri et al.26 reported that
the diameter of lung cancer significantly decreased from 37.7
mm during 1989–1998 to 28.7 mm during 1999–2008. In
this study, tumor size of resected stage I NSCLC significantly
decreased from 3.2 cm during 1980–2000 to 2.8 cm during
2001–2006. Since tumor size is a prognostic factor of overall
survival (p  0.001), the decrease of tumor size may be a
contributing factor for the improved overall survival over
time. A new classification of lung adenocarcinoma has been
published recently, and former BAC was redefined.33 We
examined the prognostic value of lung cancer detected by
chest CT screening and “BAC component” by univariate
analysis in patients with adenocarcinoma. Lung cancer de-
tected by chest CT screening did not influence overall sur-
vival, whereas BAC component was a significant prognostic
factor in patients with adenocarcinoma. BAC component was
still a significant prognostic factor for better overall survival in
multivariate analysis. Therefore, the increased percentage of
“adenocarcinoma with BAC component” was a cause of im-
proved overall survival. In our study, only 3.9% of patients were
FIGURE 4. Overall survival in patients undergoing (A) lo-
bectomy or sublobar resection and (B) pneumonectomy or
bilobectomy, for stage I non-small cell lung cancer accord-
ing to time periods 1980–1990, 1991–2000, and 2001–
2006. The log-rank test was used to compare between
groups.
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detected by chest CT screening in the last period. The prognostic
effect of chest CT screening needs further investigation.
Increased number of mediastinal lymph nodes dissected/
sampled and increased number of mediastinal lymph node
stations dissected/sampled may also lead to improved sur-
vival. In our previous studies, we have shown that the number
of mediastinal lymph nodes dissected/sampled may alterna-
tively represent the quality of lymphadenectomy and affects
the survival rate for patients with resected stage I
NSCLC.18,19 Therefore, number of mediastinal lymph nodes
dissected/sampled could be used as a marker of adequate
mediastinal lymph node dissection/sampling. In this study,
both number of mediastinal lymph nodes and lymph node
stations dissected increased over time. These factors may
contribute to more accurate tumor staging and thus the
improved survival outcome over time.
Lung cancer is a disease more prevalent in men than in
women.1,2,34 In report by Devesa et al.35 regarding interna-
tional lung cancer trends, they showed that total lung cancer
incidence rates have been declining among males in many
areas, whereas rates among females have been rising rapidly
virtually everywhere. In the United States, the male/female
lung cancer incidence ratio decreased from 3.65 in 1975 to
1.65 in 1999.34 In this study, the percentage of female patients
increased from 15.4 to 32.0% over the past three decades.
The male/female ratio significantly decreased during each
period: 5.5, 3.0, and 2.1, respectively. Since female gender is
a prognostic factor for better overall survival (p  0.001),
increased percentage of female patients may also contribute
to improved overall survival over time. We further showed
that for female patients, the overall survival rate in time
period 2001–2006 was significantly better than those in
1980–1990 and 1991–2000.
The most common subtypes of NSCLC are squamous
cell carcinomas and adenocarcinomas worldwide.2,35 Squa-
mous cell carcinoma has decreased in the past decades and
there has been an increase in adenocarcinomas in both sexes.2
Hanagiri et al.26 reported that the percentage of adenocarci-
noma significantly increased from 52.2% during 1989–1998
to 66.5% during 1999–2008, whereas the percentage of
squamous cell carcinoma significantly decreased from 36.2 to
24.2%. In our patients, the percentage of adenocarcinoma
increased from 51.2 to 74.9% over the past three decades.
Meanwhile, the percentage of squamous cell carcinoma de-
creased from 45.4 to 19.7%. The reciprocal change of squa-
mous cell carcinoma and adenocarcinoma is widely accepted
been caused by the modifications in cigarette design (filter
use) and composition.2,36 As adenocarcinoma is a favorable
prognostic factor for overall survival (p  0.001), increased
percentage of patients with adenocarcinoma may also con-
tribute to improved overall survival over time. We further
demonstrated that the overall survival rate in patients with
adenocarcinoma kept improving during the three time peri-
ods. However, no survival improvement was observed in
patients with squamous cell carcinoma.
Complete anatomical resection, including pneumonec-
tomy, bilobectomy, and lobectomy, with radical lymph node
dissection remains the standard treatment for patients with
early-stage NSCLC.37 However, pneumonectomy is associ-
ated with high postoperative mortality and morbidity rates. In
our study, the percentage of pneumonectomy or bilobectomy
decreased from 27.7 to 3.2%, whereas the percentage of
lobectomy or sublobar resection increased from 72.3 to
96.8% over time. For patients undergoing lobectomy or
sublobar resection, the overall survival rate kept improving
during the three time periods. However, no survival improve-
ment was observed in patients undergoing pneumonectomy
or bilobectomy. Kozower et al.38 reported that pneumonec-
tomy and bilobectomy were predictors of increased risk of
mortality and morbidity after surgery. Patients undergoing
pneumonectomy for early-stage NSCLC had worse long-term
survival compared with those treated by lesser resec-
tions.39–41 Poor long-term survival may be a contributing
factor leading to no improvement of overall survival in
patients undergoing pneumonectomy.
The strength of the study is that this cohort contains a
large number of patients in a single institution with long study
period and follow-up time. Our database provided useful
information for the study of time trends in survival of path-
ological stage I NSCLC. There are some limitations of this
study that should be mentioned. As a retrospective study with
long study period, lacking of data in some patients for
some variables are inevitable. Another limitation was that
not all patients had received radical mediastinal lymph
nodes dissection in our cohort. However, we provided the
number of mediastinal lymph nodes dissected/sampled for
quality control.
In conclusion, the overall survival in patients of stage I
NSCLC significantly improved during the last three decades.
Stage migration, improved postrecurrence survival, increased
frequencies of female gender and adenocarcinoma, and de-
creased tumor size lead to better overall survival.
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